Angiotensin (1-7) vs Ovagen

Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.

Angiotensin-(1-7) [Ang-(1-7)] is an endogenous heptapeptide hormone generated primarily through cleavage of angiotensin II by ACE2, functioning as a counter-regulatory arm of the renin-angiotensin system (RAS) by binding the Mas receptor to promote vasodilation, anti-fibrotic, anti-inflammatory, and cardioprotective effects that oppose the vasoconstrictive actions of angiotensin II. Ang-(1-7) acts through the ACE2/Mas receptor axis to reduce oxidative stress, attenuate NF-kB-mediated inflammation, and suppress TGF-beta fibrosis signaling; the ACE2/Ang-(1-7)/Mas axis has emerged as a key regulatory pathway in cardiovascular and metabolic disease, and gained renewed research attention given ACE2's role as the SARS-CoV-2 entry receptor. A Phase 1-2 randomized clinical trial of Ang-(1-7) infusion in COVID-19 ICU patients reported preliminary safety, tolerability, and dose-response data, providing the primary indexed human pharmacokinetic evidence; broader cardiovascular protective applications are supported by preclinical data but have not been established by completed Phase 3 trials. Ang-(1-7) has no FDA approval and no approved therapeutic indication in any jurisdiction; it is an endogenous peptide under active clinical investigation as a candidate for cardiovascular, metabolic, and inflammatory conditions, with emerging human safety data but an incomplete evidence base for any specific approved clinical use.

Liver-targeted peptide complex modulating hepatocyte gene expression. Supports liver cell regeneration, enzyme function normalization, and hepatic protein synthesis.

Ovagen is a Khavinson-class peptide bioregulator derived from ovarian tissue, developed through Vladimir Khavinson's systematic organ-specific bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology, and proposed to restore gene expression and physiological function in aging ovarian tissue by interacting with chromatin regulatory elements in target cells. As an ovarian tissue-derived bioregulator, Ovagen is positioned within the Khavinson framework as a compound designed to modulate transcription in Leydig and granulosa cells, potentially influencing estrogen synthesis, follicular function, and reproductive aging; the class-level mechanistic research has characterized how short Khavinson peptides bind DNA regulatory sequences to activate tissue-specific gene expression programs. Published research on the Khavinson peptide bioregulator class as a whole documents the systematic discovery and characterization of organ-specific peptides, with class-level evidence from animal models and human observational studies demonstrating restorative effects on tissue-specific physiological parameters across multiple organ systems. Ovagen has no FDA approval and no approved indication in any Western jurisdiction; no indexed PubMed studies specifically characterize ovagen's clinical outcomes in human subjects, and the compound is available only through the Russian bioregulator market under the class-level evidence framework established by the Khavinson group's published research.